These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 3937500)

  • 41. Pharmacokinetics of mebudipine, a new calcium antagonist, following single intravenous and oral administrations in rats.
    Bohlooli S; Keyhanfar F; Mahmoudian M
    Biopharm Drug Dispos; 2004 May; 25(4):187-91. PubMed ID: 15108221
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Inhibition of platelet aggregation by diltiazem. Comparison with verapamil and nifedipine and inhibitory potencies of diltiazem metabolites.
    Kiyomoto A; Sasaki Y; Odawara A; Morita T
    Circ Res; 1983 Feb; 52(2 Pt 2):I115-9. PubMed ID: 6831645
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effects of hemodynamic changes on the elimination kinetics of verapamil and nifedipine.
    Hamann SR; Blouin RA; Chang SL; Kaltenborn KE; Tan TG; McAllister RG
    J Pharmacol Exp Ther; 1984 Nov; 231(2):301-5. PubMed ID: 6491984
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effects of calcium entry blockers on blood pressure and heart rate in neurogenic hypertensive dogs.
    Montastruc P; Valet P; Dang Tran L; Gaillard G; Montastruc JL
    Fundam Clin Pharmacol; 1987; 1(2):85-94. PubMed ID: 3500100
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Use of calcium entry blockers in elderly patients. Special considerations.
    Wei JY
    Circulation; 1989 Dec; 80(6 Suppl):IV171-7. PubMed ID: 2688981
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Characterization of binding of the Ca++ channel antagonist, [3H]nitrendipine, to guinea-pig ileal smooth muscle.
    Bolger GT; Gengo P; Klockowski R; Luchowski E; Siegel H; Janis RA; Triggle AM; Triggle DJ
    J Pharmacol Exp Ther; 1983 May; 225(2):291-309. PubMed ID: 6842393
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Enhanced bioavailability of verapamil after oral administration with hesperidin in rats.
    Piao YJ; Choi JS
    Arch Pharm Res; 2008 Apr; 31(4):518-22. PubMed ID: 18449511
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Poisoning due to calcium antagonists. Experience with verapamil, diltiazem and nifedipine.
    Pearigen PD; Benowitz NL
    Drug Saf; 1991; 6(6):408-30. PubMed ID: 1793522
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Calcium antagonists. Mechanisms, therapeutic indications and reservations: a review.
    Opie LH
    Q J Med; 1984; 53(209):1-16. PubMed ID: 6324268
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effect of calcium channel blockers on theophylline disposition.
    Sirmans SM; Pieper JA; Lalonde RL; Smith DG; Self TH
    Clin Pharmacol Ther; 1988 Jul; 44(1):29-34. PubMed ID: 3391002
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The binding of the calcium channel blocker, bepridil, to calmodulin.
    Itoh H; Tanaka T; Mitani Y; Hidaka H
    Biochem Pharmacol; 1986 Jan; 35(2):217-20. PubMed ID: 3484629
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Allosteric modulation by diltiazem and verapamil of [3H]nitrendipine binding to calcium channel sites in rat brain.
    Schoemaker H; Boles RG; Roeske WR; Yamamura HI
    Proc West Pharmacol Soc; 1983; 26():219-24. PubMed ID: 6310626
    [No Abstract]   [Full Text] [Related]  

  • 53. Clinical pharmacological aspects of calcium antagonists and their therapeutic role in hypertension.
    Reid JL; Meredith PA; Pasanisi F
    J Cardiovasc Pharmacol; 1985; 7 Suppl 4():S18-20. PubMed ID: 2412006
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Bepridil. A review of its pharmacological properties and therapeutic use in stable angina pectoris.
    Hollingshead LM; Faulds D; Fitton A
    Drugs; 1992 Nov; 44(5):835-57. PubMed ID: 1280569
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Comparative study of vascular effects of four calcium antagonists using a multi-organ functional imaging technique with thallium-201.
    Moins N; Gachon P; Maublant J; Duchêne-Marullaz P
    J Cardiovasc Pharmacol; 1983; 5(6):978-82. PubMed ID: 6196570
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Changes in antipyrine and indocyanine green kinetics during nifedipine, verapamil, and diltiazem therapy.
    Bauer LA; Stenwall M; Horn JR; Davis R; Opheim K; Greene L
    Clin Pharmacol Ther; 1986 Aug; 40(2):239-42. PubMed ID: 3731687
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Kinetics and dynamics of calcium entry antagonists in systemic hypertension.
    McAllister RG; Schloemer GL; Hamann SR
    Am J Cardiol; 1986 Feb; 57(7):16D-21D. PubMed ID: 3513512
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Pharmacokinetics of calcium antagonists under development.
    Abernethy DR; Schwartz JB
    Clin Pharmacokinet; 1988 Jul; 15(1):1-14. PubMed ID: 3042243
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Lipid emulsion alleviates the vasodilation and mean blood pressure decrease induced by a toxic dose of verapamil in isolated rat aortae and an in vivo rat model.
    Ok SH; Shin IW; Lee SH; Park J; Woo MS; Hong JM; Kim J; Sohn JT
    Hum Exp Toxicol; 2018 Jun; 37(6):636-646. PubMed ID: 28741374
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effect of glycyrrhizic acid on protein binding of diltiazem, verapamil, and nifedipine.
    Lee KJ; Park HJ; Shin YH; Lee CH
    Arch Pharm Res; 2004 Sep; 27(9):978-83. PubMed ID: 15473671
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.